Women with polyendocrine metabolic ovarian syndrome (PMOS) are being advised to have yearly NHS check-ups to help doctors identify the various health complications linked to this intricate condition. Previously known as polycystic ovary syndrome, PMOS impacts about one in eight women and was renamed in May to better represent its far-reaching effects on health. The latest draft guidance from health regulator NICE calls for quicker diagnoses and improved monitoring for women suffering from this syndrome.
Now, PMOS stands out as a significant factor in female infertility. Symptoms can range from irregular periods and excessive hair growth to weight gain, which can lead to serious health concerns. Astonishingly, between three and four million women in the UK are believed to have this condition, but many remain undiagnosed or poorly managed, according to NICE. The recommendation suggests that these new annual check-ups should not only focus on the primary symptoms but also consider long-term risks associated with PMOS, such as diabetes and heart disease.
NICE emphasizes that lifestyle changes, alongside treatment, could potentially stave off more severe health issues. While there’s no definitive cure for PMOS, the NHS does offer various treatments to manage symptoms – ranging from hormone support to fertility drugs. However, the guidance notably states that laser and light therapies aimed at hair reduction are not recommended due to their high costs.
Sharon Manship, who has battled PMOS for 30 years, shared her experience with the condition, revealing that it took her more than a decade to receive a proper diagnosis. Sharon, a member of the committee that developed the new guidelines, initially sought support in her early 20s but struggled to get the answers she needed. She believes that the name change to PMOS is a more accurate representation of the condition and urges others to consider this when assessing symptoms and reproductive health.
NICE’s recommendation for a “simple” annual review is viewed as an essential step forward. The draft guideline is open for consultation until August 11, 2026, with NICE inviting feedback from healthcare professionals, patients, and the wider public. The final guideline on PMOS is expected to be published in December 2026, leaving many hopeful for a better understanding and management of this condition in the future.
So, what does this mean for women diagnosed with PMOS? Will these new guidelines lead to faster diagnoses and better health outcomes? Only time will tell, but it seems like a promising step in the right direction.
Kaynak: Orijinal Haber